Mark Fesler
4 months 2 weeks
This article is a nice review of genetic abnormalities associated with myeloma, yet much remains to be learned about the mechanisms of progression and varying rates of such complications
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received ..... see more
The Proximal Tubule Toxicity of Immunoglobulin Light Chains - PubMed
Plasma and B cells dyscrasias that overproduce monoclonal immunoglobulin free light chains (FLCs) affect the kidney frequently in various ways. The hematologic dyscrasia responsible for the production of FLCs may ..... see more
Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient - PubMed
Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM). In our previous report, CD19- and BCMA-targeted CAR-T co-administration was associated with a high response ..... see more
How to Treat High-Risk Myeloma at Diagnosis and Relapse - PubMed
Survival in multiple myeloma has improved greatly during the past 2 decades, but this change has primarily benefited patients who have standard-risk disease. Patients with high-risk disease remain a challenge ..... see more
When and How to Treat Relapsed Multiple Myeloma - PubMed
The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease ..... see more
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab - PubMed
doi: 10.1038/s41408-021-00478-4. 1 Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 2 Unité Hémopathies Lymphoïdes, CHU Henri Mondor, Créteil, France. 3 Service d'hématologie, CHRU Hôpitaux de ..... see more
tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma - PubMed
doi: 10.1186/s12859-021-04167-8. 1 Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, 410000, China. 2 Department of Blood Transfusion, The Seventh Affiliated Hospital of Sun Yat-Sen University, ..... see more
Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma - PubMed
doi: 10.3389/fgene.2021.665173. 1 Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China. 2 Department of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ..... see more
Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods - PubMed
doi: 10.1002/jmri.27637. Online ahead of print. 1 Department of Radiology, Peking University Third Hospital, Haidian District, Beijing, People's Republic of China. 2 Huiying Medical Technology (Beijing) Co., Ltd, Beijing, China. ..... see more
Multiple myeloma presenting as cryoglobulinemic vasculitis - PubMed
doi: 10.1016/j.jdcr.2021.03.026. 1 Medical School, University of Michigan, Ann Arbor, Michigan. 2 Ochsner Health Center, New Orleans, Louisiana. 3 Department of Pathology, University of Michigan, Ann Arbor, Michigan. 4 Division ..... see more
MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance - PubMed
Multiple myeloma (MM) is a common malignant hematological malignancy. Recently, interest has grown in the role of non-coding regions in disease pathogenesis. MicroRNAs (miRNAs) are small non-coding RNAs containing 19-25 ..... see more
Evaluation of an open-source machine-learning tool to quantify bone marrow plasma cells - PubMed
doi: 10.1136/jclinpath-2021-207524. Online ahead of print. 1 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada [email protected] 2 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, ..... see more
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome - PubMed
DIS3 gene mutations (DIS3mts) occur in roughly 10% of multiple myeloma (MM) patients; furthermore, DIS3 expression could be affected by monosomy 13 or del(13q), which occur in approximately 40% of ..... see more
Evaluation of an open-source machine-learning tool to quantify bone marrow plasma cells - PubMed
doi: 10.1136/jclinpath-2021-207524. Online ahead of print. 1 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada [email protected] 2 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, ..... see more
Genetic Predictors of Mortality in Multiple Myeloma | TACG
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. The disease is virtually always preceded by an asymptomatic stage named monoclonal gammopathy of undetermined ..... see more
Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma - PubMed
doi: 10.3324/haematol.2020.277152. Online ahead of print. 1 Department of Medicine I, Wilhelminen Cancer Research Institute, Clinic Ottakring, Vienna, Austria; Recipient of a DOC Fellowship of the Austrian Academy of Sciences ..... see more
Show More Comments
-
Mark Fesler 4 months 2 weeks
Will be interesting to see if this bench research on myeloma cell lines can be translated into a clinically useful combination strategy at the bedside
Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma - PubMed
Patients with depression had a substantially high risk of poor adherence compared to patients without depression. Given that Rd treatment is mainly offered by outpatient clinics, active interventions to reduce ..... see more
Show More Comments
-
Mark Fesler 4 months 3 weeks
Very important topic linking compliance and ultimately effectiveness of oral antineoplastic therapy with depression
Clinical outcomes and complications of surgical interventions for multiple myeloma lesions in the extremities and pelvis: A retrospective clinical study - PubMed
Objective: This study aimed to assess the pain and functional status of patients who underwent various surgical interventions for the stabilization of selected multiple myeloma (MM) lesions in the extremities ..... see more
Show More Comments
-
Mark Fesler 5 months
Location rather than the disease seems to best reflect the outcome of surgical intervention for skeletal related cancer complications
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients - PubMed
The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed ..... see more
Show More Comments
-
Mark Fesler 5 months
Small numbers in this retrospective analysis. At most hypothesis generating but seems unlikely that this will see additional work
Bleeding Diathesis in Multiple Myeloma: A Rare Presentation of a Dreadful Emergency With Management Nightmare - PubMed
Multiple myeloma is a neoplastic disorder of plasma cells. An abnormal coagulation profile, though commonly seen in multiple myeloma, can rarely manifest as life-threatening hemorrhagic complications. Bleeding tendencies in multiple ..... see more
Show More Comments
-
Mark Fesler 5 months
This is a case report of a very rare complication of a relatively common disease. Report reflects the fact that malignant hematologists sometimes have to work through complex benign hematological Show More
Show More Comments
Valuable piece as our best intended instructions don’t always “reach” the patient and while hopefully uncommon, this can be a resource for a practicing clinician
Please share your thoughts concerning overdose on oral chemotherapy.